KEEP IT SIMPLE - Imprimis Pharmaceuticals

Why LessDrops™?
brought to you by
Combination Drop Therapy is a way to significantly reduce
KEEP IT SIMPLE
the number of eye drops needed after ocular surgeries. This
approach alleviates the need for multiple postoperative
drops and, in turn, helps cut medication costs. Developed
with your patients top-of-mind, our proprietary topical
compounded formulations aim to improve patient
compliance and alleviate patient confusion with fewer
drops, meaning they will be better able to follow the
regimen you prescribe.
Unique Steroid, Antibiotic, and Nonsteroidal Combinations
COMMONLY REPORTED PATIENT
COMPLIANCE ISSUES AFTER OCULAR SURGERY1,2
FEWER DROPS + LOWER COSTS.
PRED-MOXI
TRI-MOXI
• Daily dose frequency
Prednisolone acetate and
moxifloxacin hydrochloride
Triamcinolone acetonide and
moxifloxacin hydrochloride
• Using an incorrect amount of drops
• Instillation technique
PRED-KETOR
PRED-MOXI-KETOR
Prednisolone acetate and
ketorolac tromethamine
Prednisolone acetate, moxifloxacin
hydrochloride, and ketorolac
tromethamine
• Forgetfulness
• Inconvenience
• Unaffordability
Place an order today at
www.LessDrops.com/orders
References: 1. Patel SC, Spaeth GL, Compliance in patients prescribed eyedrops for glaucoma.
Ophthalmic Surg. 1995;26(3):233-236. 2. An JA, Kasner O, Samek DA, Lévesque V. Evaluation of
eyedrop administration by inexperienced patients after cataract surgery. J Cataract Refract Surg.
ABOUT SSP TECHNOLOGY™
Compounding with an Imprimis Pharmacy
Proprietary ophthalmic compounded formulations from
Imprimis Pharmaceuticals are enabled by our patent-pending
SSP Technology™, which allows active pharmaceutical
ingredients (APIs) that ordinarily do not mix to solubilize into a
predictable, well-distributed, micronized particle suspension.
At Imprimis Pharmaceuticals, we are committed to delivering high quality formulations that
meet or exceed stringent U.S. Pharmacopeia (USP) guidelines.
Our drug formulations with SSP Technology are optimized
for isotonicity and pH compatibility for ophthalmic use.
The result is a variety of new sterile combination drug
formulations, either as injectable or topical therapies
compounded to meet your patients’ specific needs.
The formulations have been optimized for the isotonicity and pH most compatible with the
eye, and their particle size has been homogenized to smoothly dispense in the vitreous upon
injection through a small cannula. Additionally, every batch is tested for sterility and bacterial
endotoxins.
We can provide many other compounded medications to meet your patients’ needs.
Contact an Imprimis pharmacist today at [email protected]
DYNALABS Continuous Quality
Improvement (CQI) // PCAB ACCREDITED
The LessDrops™ educational campaign is brought to you by San Diego-based Imprimis
Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company dedicated to delivering
high quality, novel, and customizable medicines to physicians and patients at accessible prices.
Without our SSP Technology, large irregular
un-usable clumps of active drugs persist.
For more information on Imprimis, visit www.imprimispharma.com
brought to you by
Our SSP Technology™ allows active drugs to
mix and become usable as an injections or as a
combination eye drop.
*Compounded by a pharmacist pursuant to a prescription to meet the needs of individual patients. May be customized.
LessDrops, Dropless Therapy, and SSP Technology are trademarks of Imprimis Pharmaceuticals, Inc.
©2015 Imprimis Pharmaceuticals, Inc. All Rights Reserved. IMPO00XX 04/15